| Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Drug development in higher-risk myelodysplastic syndromes |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia |
|
Blood Cancer Journal |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
|
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
| Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years |
|
Blood Advances |
Aplastic Anemia |
| Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy |
|
Blood Advances |
Aplastic Anemia |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
